[1] Liu T, Song D, Dong J, et al. Current understanding of the pathophysiology of myocardial fibrosis and its quantitative assessment in heart failure[J]. Front Physiol, 2017, 8: 238.doi:10.3389/fphys.2017.00238. [2] Frangogiannis N. Can myocardial fibrosis be reversed?[J]. J Am Coll Cardiol, 2019, 73: 2283-2285. [3] Díez J, González A, Kovacic J. Myocardial interstitial fibrosis in nonischemic heart disease, part 3/4: JACC focus seminar[J]. J Am Coll Cardiol, 2020, 75: 2204-2218. [4] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2016, 37: 2129-2200. [5] Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Associa-tion Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiova-scular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons[J]. Circulation, 2014, 130: 1749-1767. [6] Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases[J]. Eur Heart J, 2016, 37: 1850-1858. [7] Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2014, 35: 2733-2779. [8] Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J]. Eur Heart J, 2013, 34: 2636-2648, 2648a-2648d. [9] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hyperten-sion[J]. Eur Heart J, 2018, 39: 3021-3104. [10] Slimani A, Melchior J, de Meester C, et al. Relative contribution of afterload and interstitial fibrosis to myocardial function in severe aortic stenosis[J]. JACC Cardiovasc Imaging, 2020, 13: 589-600. [11] Kwiecinski J, Lennen R, Gray G, et al. Progression and regression of left ventricular hypertrophy and myocardial fibrosis in a mouse model of hypertension and concomitant cardiomyopathy[J]. J Cardiovasc Magn Reson, 2020, 22: 57.doi:10.1186/s12968-020-00655-7. [12] Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respira-tory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)[J]. Eur Heart J, 2016, 37: 67-119. |